ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1378

the Impact of Rheumatoid Arthritis Activity and Medications on Pregnancy Outcomes

Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: pregnancy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose:   While rheumatoid arthritis (RA) has historically improved in pregnancy, recent studies suggest the improvement may not be dramatic now that we are able to control the disease better outside of pregnancy. TNF inhibitors are now routinely continued during pregnancy for women with inflammatory bowel disease (IBD) because active IBD is associated with pregnancy morbidity.  The link between RA activity and pregnancy outcomes, however, is less clear.  We sought to explore the role that RA activity and medications play in pregnancy outcomes. 

Methods:   Pregnancies in women with RA from a prospective registry were reviewed to determine the extent that RA activity and medications in the 1st and 2nd trimesters impacted pregnancy outcomes. Disease activity was divided into 2 levels based on the worst DAS-CRP3 and/or physician’s global assessment in the first 24 weeks of pregnancy.  Chi-square and non-parametric tests were used for univariate analysis.   A general estimating equation was used in multivariate analysis to account for multiple pregnancies in some women. 

Results: A total of 31 pregnancies in 25 women with RA or JIA were enrolled in the registry before 24 weeks gestation.  Seven pregnancies were in women with JIA and 24 with adult-onset RA.  Two ended with first trimester miscarriages; both in women with low RA activity without prednisone or TNF inhibitor exposure, but one took methotrexate in pregnancy.  Of the remaining 29 pregnancies, 15 (51.7%) had RA that was either mild or in remission throughout the 1st and 2nd trimesters and 14 (48.3%) had RA that was moderately to severely active during this period.  6 of 29 (20.7%) live births had poor outcomes: 4 with preterm delivery, 1 with preeclampsia, and 1 with preterm preeclampsia. 

The rate of Sulfasalazine (SSZ), hydroxychloroquine (HCQ), and TNF inhibitor use was not statistically different for women with low vs high RA activity.  Women with high RA activity, however, were more likely to take prednisone (57.1% vs 13.3%, p=0.02).

Significantly more women with preterm birth and/or preeclampsia had moderate/severe RA in early pregnancy (see table).  While not statistically significant, more pregnancies with poor outcomes were exposed to prednisone and fewer to TNF inhibitors early in pregnancy.   SSZ and HCQ were not associated with pregnancy outcomes.  Methotrexate was associated with preterm birth. 

A logistic regression model demonstrated that lower RA activity and use of a TNF inhibitor in the 1st and 2nd trimesters were associated with term birth without preeclampsia.  Taking prednisone in the first half of pregnancy did not appear to impact pregnancy outcomes.  

Conclusion: In this era of treat-to-target management of RA, our paradigm for RA pregnancy management may need adjusting.  By controlling RA activity with medications considered relatively safe in pregnancy, we may be able to improve both the pregnancy experience and pregnancy outcomes.

Table:  RA activity and medications in the 1st and 2nd trimesters of pregnancy for live births:

All Live Births

Full term delivery

without preeclampsia

Preterm delivery

and/or preeclampsia

p-value

Number of live births

29

23 (79.3%)

6 (20.7%)

Moderate/severe RA

14 (45.2%)

8 (34.8%)

6 (100%)

0.006

Physician’s Global Assessment

63.7 (22.6)

Mean 69.9 (SD 20.1)

Range: 25-100

Mean 40 (SD 15.2)

Range: 20-60

0.005

Any prednisone use

10 (34.5%)

6 (26.1%)

4 (66.7%)

0.143

Prednisone dose

9.5mg (5.37)

10mg (SD 6.89)

Range: 2.5-20mg

8.75mg (SD 2.5)

Range: 5-10mg

0.83

Sulfasalazine

7 (24.1%)

6 (26.1%)

1 (16.7%)

0.55

Hydroxychloroquine

13 (44.8%)

11 (47.8%)

2 (33.3%)

0.44

Methotrexate

2 (6.9%)

0

2 (33.3%)

0.037

TNF inhibitor use

9 (31.0%)

8 (34.8%)

5 continuous

3 started in pregnancy

1 (16.7%)

1 started in pregnancy

0.38


Disclosure:

M. E. B. Clowse,

UCB Pharma,

5;

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-rheumatoid-arthritis-activity-and-medications-on-pregnancy-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.